The hypothesis that the results of second line hormonotherapy for breast cancer may be ameliorated with continuation of the first line has been explored in a randomized trial. Patients progressing under tamoxifen were randomly allocated to aminoglutethimide and hydrocortisone acetate with or without tamoxifen continuation. No difference has been observed between the two arms in terms of response rate and progression-free or overall survival.
|Number of pages||4|
|Journal||American Journal of Clinical Oncology: Cancer Clinical Trials|
|Publication status||Published - 1993|
ASJC Scopus subject areas
- Cancer Research